B. Riley Issues Positive Estimate for Altimmune Earnings

Altimmune, Inc. (NASDAQ:ALT) – Equities researchers at B. Riley raised their Q2 2025 earnings per share estimates for shares of Altimmune in a research note issued on Wednesday, May 14th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of ($0.27). The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. B. Riley also issued estimates for Altimmune’s Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.25) EPS.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. During the same quarter in the previous year, the business posted ($0.34) EPS.

Other equities research analysts have also recently issued research reports about the company. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, April 3rd. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $20.20.

Altimmune Price Performance

NASDAQ:ALT opened at $5.58 on Friday. The stock has a market cap of $429.74 million, a PE ratio of -3.60 and a beta of 1.13. The stock’s 50-day moving average is $5.11 and its two-hundred day moving average is $6.56. Altimmune has a fifty-two week low of $3.55 and a fifty-two week high of $11.16.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ALT. 180 Wealth Advisors LLC acquired a new position in shares of Altimmune during the fourth quarter worth approximately $78,000. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Altimmune by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company’s stock worth $1,482,000 after buying an additional 31,482 shares during the last quarter. Kraematon Investment Advisors Inc. acquired a new position in shares of Altimmune in the fourth quarter valued at $222,000. SG Americas Securities LLC raised its stake in shares of Altimmune by 36.7% in the fourth quarter. SG Americas Securities LLC now owns 47,060 shares of the company’s stock valued at $339,000 after purchasing an additional 12,624 shares in the last quarter. Finally, PFG Investments LLC acquired a new position in shares of Altimmune in the fourth quarter valued at $96,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.